ACUTE NONSPECIFIC DIARRHEA

Bar graph comparing the time to last liquid stool after initial dose of Motofen versus placebo. Reference: 1.

	Number of patients
Time to last liquid stool after initial dose¹	Motofen (n of 38)	Placebo (n of 37)
0 to 4 hours	22	8
5 to 9 hours	5	8
10 to 14 hours	3	4
15 to 19 hours	3	4
20 to 24 hours	1	8

57% of patients had their last liquid stool in 4 hours or less after an initial 2-mg dose of Motofen.¹

Of the 38 patients taking Motofen, 79% achieved relief by 24 hours and 92% achieved relief in 48 hours (P value less than 0.01 versus placebo). Reference: 1.

Motofen improves stool consistency and frequency within 24 to 48 hours.¹ More than half of patients (79%) achieved relief of their diarrhea with Motofen within the first 24 hours, and 92% achieved relief within 48 hours.¹

Click below to review the full poster on Motofen data

Important Safety Information

INDICATIONS AND USAGE: Motofen^® (difenoxin and atropine sulfate tablets) is indicated as adjunctive therapy in the management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea.
CONTRAINDICATIONS: Motofen^® is contraindicated in patients with diarrhea associated with organisms that penetrate the intestinal mucosa (toxigenic E. coli, Salmonella species, Shigella) and pseudomembranous colitis associated with broad spectrum antibiotics.
Motofen^® is also contraindicated in children under 2 years of age, in patients with known hypersensitivity to difenoxin, atropine, or any of the inactive ingredients, and in patients who are jaundiced.
WARNINGS AND PRECAUTIONS: Motofen^® is not an innocuous drug and dosage recommendations should be strictly adhered to. Accidental overdose may result in severe respiratory depression and coma, possibly leading to permanent brain damage or death.
The use of Motofen^® does not preclude the administration of appropriate fluid and electrolyte therapy. Dehydration, particularly in children, may further influence the variability of response to Motofen^® and may predispose to delayed difenoxin intoxication. Drug-induced inhibition of peristalsis may result in fluid retention in the colon, and this may further aggravate dehydration and electrolyte imbalance.
Use with caution in patients with ulcerative colitis or liver or kidney disease.
Motofen^® may produce drowsiness or dizziness. Use caution when engaging in activities requiring mental alertness, such as driving or operating dangerous machinery.
Safety and effectiveness in children below the age of 12 have not been established.
Keep out of reach of children.

Please click here for full Prescribing Information

REFERENCES: 1. Data on file, Sebela Pharmaceuticals. 2. Motofen [package insert]. Roswell, GA: Sebela Pharmaceuticals; August 2018. 3. Lomotil Tablets [package insert]. New York, NY: Pfizer Inc.; 2018.

Lomotil is a registered trademark of Pfizer Inc.

Important Safety Information

INDICATIONS AND USAGE: Motofen^® (difenoxin and atropine sulfate tablets) is indicated as adjunctive therapy in the management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea.
CONTRAINDICATIONS: Motofen^® is contraindicated in patients with diarrhea associated with organisms that penetrate the intestinal mucosa (toxigenic E. coli, Salmonella species, Shigella) and pseudomembranous colitis associated with broad spectrum antibiotics.
Motofen^® is also contraindicated in children under 2 years of age, in patients with known hypersensitivity to difenoxin, atropine, or any of the inactive ingredients, and in patients who are jaundiced.
WARNINGS AND PRECAUTIONS: Motofen^® is not an innocuous drug and dosage recommendations should be strictly adhered to. Accidental overdose may result in severe respiratory depression and coma, possibly leading to permanent brain damage or death.
The use of Motofen^® does not preclude the administration of appropriate fluid and electrolyte therapy. Dehydration, particularly in children, may further influence the variability of response to Motofen^® and may predispose to delayed difenoxin intoxication. Drug-induced inhibition of peristalsis may result in fluid retention in the colon, and this may further aggravate dehydration and electrolyte imbalance.
Use with caution in patients with ulcerative colitis or liver or kidney disease.
Motofen^® may produce drowsiness or dizziness. Use caution when engaging in activities requiring mental alertness, such as driving or operating dangerous machinery.
Safety and effectiveness in children below the age of 12 have not been established.
Keep out of reach of children.

Lomotil is a registered trademark of Pfizer Inc.